News and Events

Bluechiip Limited (ASX:BCT, 'Bluechiip'), leader in the development of sample tracking technology for harsh environments, is pleased to announce that in accordance with the license and supply agreement announced on the 3rd December 2015 Bluechiip has now successfully completed the concept due diligence milestone and is progressing to the product development phase with its partner in the field of Assisted Reproductive Technologies (ART) and In Vitro Fertilisation (IVF) market.

Mr Andrew McLellan, Bluechiip's Managing Director & CEO, said, 'We are excited to be moving to the development phase with the achievement of this milestone, it is a very significant step for Bluechiip. Our ability to work with partners to incorporate our technologies is fundamental to our strategy and in the field of ART and IVF we are successfully working to incorporate our technologies into partner's products.'

Mr McLellan added, 'The partnership strengthens both parties' positions and most importantly ultimately leads to customer benefits in standardization, automation and traceability.'

This milestone and the associated milestone payment is a major step forward for Bluechiip and comes alongside two ongoing development agreements with confidential partners in the fields of Protein Crystallography and Cell Therapies.'

For more information:

Andrew McLellan

Managing Director / CEO

Ph: +61 3 9763 9763

andrew.mclellan@bluechiip.com

« Back

bluechiip Limited issued this content on 12 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 February 2016 03:26:24 UTC

Original Document: http://www.bluechiip.com/2016/02/bluechiip-passes-major-milestone-in-oem-partnership/